Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-selected consolidation therapy study in unresectable stage III non-small cell lung cancer
jRCT2021220007Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial of alectinib, entrectinib, pralsetinib and durvalumab in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Nov 2022; status: active, not recruiting.
02
Drugs
alectinibentrectinibpralsetinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021220007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220007.